TrumpRx.gov is a government platform launched to lower U.S. prescription drug costs by offering prices tied to those in other developed countries. The site lists over 40 branded drugs, mainly focusing on expensive GLP-1 medications for diabetes and obesity, such as Ozempic and Wegovy, at drastically reduced cash prices (up to 93% off). Users do not need insurance or accounts and can obtain coupons to use at participating pharmacies. The initiative aims to bypass traditional middlemen like insurers and pharmacy benefit managers, with supporters praising it as direct federal action on drug pricing. However, critics note TrumpRx primarily benefits uninsured or cash-paying patients, while most Americans use insurance where negotiated rates could be better or similar. Some discounts match those already available through platforms like GoodRx, raising doubts about the novelty of the savings, and concerns persist that deep discounts depend on voluntary manufacturer participation and may not last. Policy experts argue the platform sidesteps deeper reforms of the health system, questioning its sustainability and broader impact. Nonetheless, TrumpRx offers immediate relief for some patients and marks a more interventionist federal approach to drug pricing transparency.